PMA device
Mynx Vascular Closure Device
Cordis US Corporation · Device, Hemostasis, Vascular (MGB, Class III) · First FDA decision May 16, 2007, newest Jul 22, 2013Vascular access
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
5
PMA pathway
Device trials
5
Naming "Mynx"
MAUDE reports
3,643
Brand "Mynx", since 2015
PubMed studies
44
Mentioning "Mynx"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Mynx Vascular Closure Device
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 5 of 5 decisions filed under this name.
- MYNX VASCULAR CLOSURE DEVICEPMA supplement
P040044-S045 · Decided Jul 22, 2013 · 250 days after receipt · Normal 180 Day Track No User Fee
Device type: Device, hemostasis, vascular (MGB) · Cardiology
- MYNX VASCULAR CLOSURE DEVICE PRODUCT FAMILYPMA supplement
P040044-S038 · Decided Jul 21, 2011 · 55 days after receipt · Normal 180 Day Track No User Fee
Device type: Device, hemostasis, vascular (MGB) · Cardiology
- MYNX VASCULAR CLOSURE DEVICE WITH GRIP TECHNOLOGYPMA supplement
P040044-S034 · Decided Oct 4, 2011 · 369 days after receipt · Normal 180 Day Track
Device type: Device, hemostasis, vascular (MGB) · Cardiology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Mynx", any status and sponsor, newest update first.
Cordis US Corp.Not on our public-company list
NCT07246902 · 339 participants · Start Nov 24, 2025 · Primary completion Aug 26, 2026
Device: MYNX CONTROLTM VENOUS Vascular Closure Device · For: Venous Vascular Closure; Electrophysiology Study
Sites: Los Angeles, California; Palo Alto, California; Littleton, Colorado · 9 sites in all
- Evaluation of Safety and Efficacy of the Mynx Control Venous Vascular Closure Device 6F-12F vs Manual CompressionPivotal-lookingCompleted
Cordis US Corp.Not on our public-company list
NCT05554471 · 352 participants · Start Aug 30, 2022 · Primary completion Jul 11, 2023
Device: MYNX CONTROL™ Venous Vascular Closure Device 6F-12F · For: Venous Vascular Closure
Sites: Phoenix, Arizona; Lakewood, Colorado; Miami, Florida · 14 sites in all
- The Safety and Efficacy of an Extravascular, Water-Soluble Sealant for Venous Access-Site ClosurePivotal-lookingCompleted
Medstar Health Research InstituteAcademic, hospital or other
NCT02438475 · 208 participants · Start Jun 2015 · Primary completion Aug 2017
Device: Mynx Vascular Closure System · For: Cardiac Diagnostic Procedure; Cardiac Interventional Procedure; Femoral Access Site Closure
Sites: Washington D.C., District of Columbia; Clinton, Maryland
2 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Mynx", and for the whole product code for context.
This brand
3,643 reports: 2,843 malfunction, 783 injury, 11 death
Whole product code MGB
93,533 reports: 17,154 malfunction, 76,023 injury, 315 death
Newest reports for this brand
- MYNX CONTROLMalfunction
3004939290-2026-01546 · Received Oct 29, 2026 · Event dated Jul 29, 2026
Device type: Device, Hemostasis, Vascular (MGB)
Device problem as coded: Premature Activation
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- MYNX CONTROL VENOUSMalfunction
3004939290-2026-01547 · Received Oct 29, 2026 · Event dated Sep 30, 2026
Device type: Device, Hemostasis, Vascular (MGB)
Device problem as coded: Premature Activation
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- MYNX CONTROL VENOUSInjury
3004939290-2026-01548 · Received Oct 29, 2026
Device type: Device, Hemostasis, Vascular (MGB)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Thrombosis/Thrombus
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- MYNXGRIP 5F, REF MX5021, Vascular Closure Device (VCD). Used to seal femoral arterial and femoral venous access sites.Open, Classified
Z-0674-2024 · Started Nov 28, 2023 · Posted by FDA Jan 5, 2024
Reason given: Cordis became aware that the label for the carton box containing 10 units is incorrect for some boxes of two lots of MynxGrip. The carton box from lot F2322902 (Item MX5021, MynxGrip 5F) as labeled as lot F2322903 (MX6721, MynxGrip 6/7F) and product from lot F2322903 (MX6721, MynxGrip 6/7F) was labeled as F2322902...
Cause as FDA categorized it: Labeling Change Control · Device type: Device, Hemostasis, Vascular (MGB)
- MYNXGRIP 6F/7F, REF MX6721, Vascular Closure Device (VCD). Used to seal femoral arterial and femoral venous access sitesOpen, Classified
Z-0675-2024 · Started Nov 28, 2023 · Posted by FDA Jan 5, 2024
Reason given: Cordis became aware that the label for the carton box containing 10 units is incorrect for some boxes of two lots of MynxGrip. The carton box from lot F2322902 (Item MX5021, MynxGrip 5F) as labeled as lot F2322903 (MX6721, MynxGrip 6/7F) and product from lot F2322903 (MX6721, MynxGrip 6/7F) was labeled as F2322902...
Cause as FDA categorized it: Labeling Change Control · Device type: Device, Hemostasis, Vascular (MGB)
AccessClosure, Inc., A Cardinal Health Company
Z-2329-2016 · Started Jul 13, 2016 · Posted by FDA Aug 3, 2016
Reason given: A total of 70 6F/7F Mynx Grip devices were shipped from a distributor using improper transport/packaging configurations.
Cause as FDA categorized it: Process control · Device type: Device, Hemostasis, Vascular (MGB)
Published research
The most relevant PubMed records for "Mynx"[tiab]. The summary above synthesizes these.
- Evaluation of the MYNX CONTROLࡊ Arterial Closure System for Achieving Primary Hemostasis after Arterial Femoral Access Following Peripheral Arterial Interventions, Compared to the FemoSealTM Closure System.
Noory E, Böhme T, Krause L, et al. · J Clin Med · 2023
- Safety and efficacy of the Mynx Control vascular closure device in peripheral arterial procedures: A prospective study.
Diamantopoulos A, Nourzaie R, Mulholland D, et al. · Vascular · 2023
- Safety and efficacy of arterial closure devices in an office-based angiosuite.
Dham S, Ahn S · J Vasc Surg · 2025Comparative Study, Research Support, Non-U.S. Gov't
- Mynx Vascular Closure Device in Arterial Endovascular Procedures.
Scott MC, Spencer HJ, Ali AT, et al. · Ann Vasc Surg · 2018Comparative Study
- A prospective randomized single-blind trial of patient comfort following vessel closure: extravascular synthetic sealant closure provides less pain than a self-tightening suture vascular compression device.
Fargen KM, Hoh BL, Mocco J · J Neurointerv Surg · 2011Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Active Versus Passive Anchoring Vascular Closure Devices Following Percutaneous Coronary Intervention: A Safety and Efficacy Comparative Analysis.
Baker NC, Escarcega RO, Lipinski MJ, et al. · J Interv Cardiol · 2016Comparative Study
- Imaging-Guided Deployment of a Balloon-Based Vascular Closure Device in Routine Clinical Practice.
Lee WH, Lee HN, Kim SS, et al. · J Vasc Interv Radiol · 2022
- Safety and efficacy of Mynx vascular closure device for the closure of common femoral artery access after ipsilateral stent placement.
Hwang JH, Park SW, Yang WY, et al. · J Vasc Access · 2022
- Registry-Based Prospective, Active Surveillance of Medical-Device Safety.
Resnic FS, Majithia A, Marinac-Dabic D, et al. · N Engl J Med · 2017Comparative Study, Research Support, Non-U.S. Gov't
- Safety and Efficacy of a Novel "Hybrid Closure" Technique in Large-Bore Arteriotomies.
Amponsah MK, Tayal R, Khakwani Z, et al. · Int J Angiol · 2017
- Femoral artery complications associated with the Mynx closure device.
Fields JD, Liu KC, Lee DS, et al. · AJNR Am J Neuroradiol · 2010
Other devices of this type
Also filed under product code MGB.
- Angio-Seal Vascular Closure DeviceTerumo Medical Corporation · PMA 2013
- Perclose ProGlide® Suture-Mediated Closure SystemAbbott Vascular, Inc. · PMA 2025
- StarClose SE® Vascular Surgical SystemAbbott Vascular Devices · PMA 2025
- MANTA Vascular Closure DeviceTeleflex Medical, LLC · PMA 2024
- Vascade Vascular Closure System (VCS)Cardiva Medical, Inc. · PMA 2023
- MynxGrip and Mynx Ace Vascular Closure DeviceCordis US Corporation · PMA 2018
- Vascular Solutions Duett Sealing DeviceVascular Solutions, Inc. · PMA 2010
- Angio-Seal Hemostatic Puncture Closure DeviceTerumo Medical Corporation · PMA 2000
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.